Dry Eye Relief® TG-1000 is the latest eye health supplement formulated by Dr. Paul Krawitz, President and Founder of VisiVite’s parent company, Vitamin Science, Inc. Dr. Krawitz holds United States Patent 7,638,142 for his Therapeutic Composition for the Treatment of Dry Eye Syndrome, also known as Dry Eye Relief® Tear Film Stabilization Formula, which has set the standard for natural dry eye care.
VisiVite Dry Eye Relief TG-1000 upgrades VisiVite's current Dry Eye Relief supplement with higher potencies of the preferred triglyceride [TG] form of Omega-3 fatty acids. TG Omega-3s are the natural form found in whole fish that are up to 70% more absorbable than the synthetic ethyl esters form found in most other dry eye supplements. Highly bioavailable, Dry Eye Relief TG-1000 encourages peak delivery of Omega-3s to the eyes’ lacrimal glands, where they soothe inflammation while promoting healthier tear production.
The eye’s surface is more complex than most people realize,” explained Dr. Krawitz. “It has an inner mucous layer, a middle aqueous layer and outer lipid layer. These layers are chemically dissimilar – they repel each other, and can be unstable. If any layer is deficient, dry eye can result… but most supplements and OTC products only address the outer layer.
Dry Eye Relief also includes Curcumin C3 Complex®, a COX-2 inhibitor that modulates inflammation without GI tract side effects. These enhancements, along with pure ingredients, easy absorption, strong safety profile and high quality standards, are why Dry Eye Relief TG-1000 brings superior results for tear production, moisture retention and overall eye comfort
Patented dry eye supplement with pharmaceutical-grade triglyceride-form omega 3s for improved absorption and efficacy, to address lacrimal gland inflammation, plant phytosterols to replace the tear's lipid layer to reduce evaporation, large mucin molecules to assist with tears binding to the cornea, and polar phospholipids to bind and stabilize the three tear layers.